Aranesp and the Breast Cancer Market Amgen received bad news regarding Aranesp in December 2007, in the form of Phase III data from breast-cancer patients on chemotherapy with hemoglobin levels above the range already specified on the Aranesp label, and interim results from the ongoing study seemed to affirm safety concerns that surfaced earlier...Yet Walsh wrote in a research note that ESA and other product inventory levels were high and could have inflated sales...There is "virtually no use" in
Aranesp history and approvals Amgen’s epoetin alpha is licensed to Ortho Biotech, except for one indication in the U.S. Outside of the U.S., Ortho markets it as Eprex for all approved indications, and inside the U.S., it is marketed as Procrit for indications other than kidney dialysis...Just ahead of the committee hearing, the Government Accountability Office released a report recommending that the drug’s reimbursement be bundled with other dialysis services that are administered hand in hand
Aranesp and the Breast Cancer Market Amgen received bad news regarding Aranesp in December 2007, in the form of Phase III data from breast-cancer patients on chemotherapy with hemoglobin levels above the range already specified on the Aranesp label, and interim results from the ongoing study seemed to affirm safety concerns that surfaced earlier...Yet Walsh wrote in a research note that ESA and other product inventory levels were high and could have inflated sales...There is "virtually no use" in